To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Active:	Yes
Cancer Type:	Lung Cancer	NCT ID:	NCT05468489
Trial Phases:	Phase III	Protocol IDs:	ASTRIDE (HLX10-005-SCLC301-E) (primary) NCI-2023-03864 ASTRIDE HLX10-005-SCLC301-E
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Shanghai Henlius Biotech
NCI Full Details:	http://clinicaltrials.gov/show/NCT05468489

Summary

This is a randomized, open-label study of Serplulimab plus chemotherapy
(Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously
untreated US patients with ES-SCLC.

Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows:

- Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide)

- Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)

Treatment Sites in Georgia

City of Hope Atlanta
600 Celebrate Life Parkway
Newnan, GA 30265
770-400-6169
www.cityofhope.org/locations/atlanta/atlanta-cancer-center

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.